Novel Biomarkers Related Xuebijing Injection Improves Sepsis
ConditionSepsis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSoutheast University, China
About this trial
Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Meeting the Sepsis 3.0 diagnostic criteria;
SOFA score ≥ 2 and < 13;
Signed informed consent.
Disqualifiers
Age <18 years or >75 years;
Pregnant or lactating women;
Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;
Current use of immunosuppressants or history of organ transplantation within the past 6 months;
Trial population
Sepsis
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
30 Participants
are grouped into 3 trial groupsGroup A: Xuebijing treatment group
Group B: Standard treatment group
Group C: Healthy Volunteer Group
Trial outcomes
Primary outcomes
1
Single-cell transcriptomic analysis of inflammatory and metabolic gene expression, measured using scRNA-seq, with data summarized as differential expression profiles.
Single-cell transcriptomic analysis of inflammatory and metabolic gene expression, measured using scRNA-seq, with data summarized as differential expression profiles.
Time frame
Day7Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: